KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Revenue (2016 - 2025)

Gilead Sciences' Revenue history spans 17 years, with the latest figure at $7.9 billion for Q4 2025.

  • For Q4 2025, Revenue rose 4.7% year-over-year to $7.9 billion; the TTM value through Dec 2025 reached $29.4 billion, up 2.4%, while the annual FY2025 figure was $29.4 billion, 2.4% up from the prior year.
  • Revenue reached $7.9 billion in Q4 2025 per GILD's latest filing, up from $7.8 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $7.9 billion in Q4 2025 to a low of $6.2 billion in Q2 2021.
  • Average Revenue over 5 years is $7.0 billion, with a median of $7.0 billion recorded in 2022.
  • Peak YoY movement for Revenue: grew 20.88% in 2021, then fell 5.11% in 2022.
  • A 5-year view of Revenue shows it stood at $7.2 billion in 2021, then increased by 2.0% to $7.4 billion in 2022, then decreased by 3.72% to $7.1 billion in 2023, then rose by 6.4% to $7.6 billion in 2024, then increased by 4.7% to $7.9 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Revenue are $7.9 billion (Q4 2025), $7.8 billion (Q3 2025), and $7.1 billion (Q2 2025).